These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 11967790

  • 1. Angiotensin II receptor blockers in chronic heart failure--not as ELITE as expected!
    Farquharson CA, Struthers AD.
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):21-2. PubMed ID: 11967790
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 4. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005 Sep; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

  • 5. A hard look at angiotensin receptor blockers in heart failure.
    Gring CN, Francis GS.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1841-6. PubMed ID: 15519017
    [Abstract] [Full Text] [Related]

  • 6. Current perspectives for AT(1)-receptor blockers in the management of heart failure.
    Swedberg K.
    J Hum Hypertens; 2002 Aug 02; 16 Suppl 3():S47-51. PubMed ID: 12140728
    [Abstract] [Full Text] [Related]

  • 7. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
    Carson PE.
    Am Heart J; 2000 Sep 02; 140(3):361-6. PubMed ID: 10966531
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE, McKinnie JJ, Greenberg SS, Giles TD.
    Prog Cardiovasc Dis; 1999 Sep 02; 41(4):265-300. PubMed ID: 10362349
    [Abstract] [Full Text] [Related]

  • 9. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 02; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 10. The therapeutic role of RAS blockade in chronic heart failure.
    Werner CM, Böhm M.
    Ther Adv Cardiovasc Dis; 2008 Jun 02; 2(3):167-77. PubMed ID: 19124420
    [Abstract] [Full Text] [Related]

  • 11. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Jun 02; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 12. Reassessing guidelines for heart failure.
    Drexler H, Wollert KC.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep 02; 5 Suppl 1():S28-33. PubMed ID: 15526240
    [Abstract] [Full Text] [Related]

  • 13. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 02; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 14. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
    Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM.
    Arch Intern Med; 2007 Oct 08; 167(18):1930-6. PubMed ID: 17923591
    [Abstract] [Full Text] [Related]

  • 15. Ongoing Clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction.
    McMurray J, Berry C.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 08; 1(2):131-6. PubMed ID: 11967803
    [No Abstract] [Full Text] [Related]

  • 16. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE, Julius S.
    Am Heart J; 2004 Nov 08; 148(5):747-54. PubMed ID: 15523303
    [Abstract] [Full Text] [Related]

  • 17. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D.
    Acta Med Croatica; 2004 Nov 08; 58(2):129-34. PubMed ID: 15208798
    [Abstract] [Full Text] [Related]

  • 18. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G, Gorini M, Maggioni AP, Di Lenarda A, Area Scompenso ANMCO, Firenze.
    G Ital Cardiol (Rome); 2007 Feb 08; 8(2):102-6. PubMed ID: 17402354
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar 08; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 20. Use of valsartan in post-myocardial infarction and heart failure patients.
    Liu PP, Maggioni A, Velazquez EJ.
    J Renin Angiotensin Aldosterone Syst; 2006 Jun 08; 7 Suppl 1():S19-22. PubMed ID: 16986231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.